Biofrontera
BFRIW
7 hedge funds and large institutions have $15K invested in Biofrontera in 2024 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 1 closing their positions.
614% more capital invested
Capital invested by funds: $2.1K → $15K (+$12.9K)
0.61% more ownership
Funds ownership: 15.95% → 16.56% (+0.61%)
0% more funds holding
Funds holding: 7 → 7 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$314 |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$70 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BA
Bard Associates
Chicago,
Illinois
|
-$118 |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$12 |
| 3 |
CS
Clear Street
New York
|
-$6 |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$1 |
BFRIW Hedge Fund Activity: Q1 2024 in Review
7 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Biofrontera (BFRIW) for Q1 2024, worth a combined $15K — up 614% from $2.1K a quarter earlier.
Fund positioning in BFRIW was balanced in Q1 2024: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 3 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $314. The largest seller was Bard Associates, cutting an estimated $118.
- 7 institutional investors held Biofrontera (BFRIW) as of Q1 2024, unchanged from Q4 2023.
- Funds reported $15K of Biofrontera stock for Q1 2024, up 614% quarter-over-quarter.
- 1 fund opened new Biofrontera positions in Q1 2024 and 1 closed out, a net change of 0 holders.
- The largest Biofrontera buyer in Q1 2024 was Citadel Advisors, an estimated $314 added.
- The largest Biofrontera seller in Q1 2024 was Bard Associates, an estimated $118 sold.
Based on aggregated 13F filings for Q1 2024.